CIDeRplusGeneral Information:
| Id: | 11,778 (click here to show other Interactions for entry) |
| Diseases: |
COVID-19
Diabetes mellitus, type II - [OMIM] Insulin resistance |
| Mammalia | |
| review | |
| Reference: | Hussain A et al.(2020) COVID-19 and diabetes: Knowledge in progress Diabetes Res. Clin. Pract. 162 [PMID: 32278764] |
Interaction Information:
| Comment | Considering that ACE2 is a functional receptor for SARS-CoV-2 and its levels can be increased by ACEIs and ARBs, it has been argued that these drugs might affect negatively the outcome of COVID-19 patients. On the contrary, some have advocated that ACEIs and ARBs might rather be beneficial. SARS-CoV infection and the virus Spike protein reduce ACE2 expression. Mice injected with SARS-CoV Spike presented worsened acute lung failure, which could be attenuated by blocking the renin-angiotensin pathway. Nevertheless, a retrospective analysis performed on 112 patients with COVID-19 and CVD did not show a significant difference in the proportion of ACEI/ARB medication between survivors and non-survivors. |
|
Formal Description Interaction-ID: 116653 |
|
| Drugbank entries | Show/Hide entries for ACE2 |